The Kidney Disease: Improving Global Outcomes (KDIGO) 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C virus (HCV) infection in chronic kidney disease (CKD) is an extensive update of KDIGO's 2008 guideline on HCV infection in CKD. This update reflects the major advances since the introduction of directacting antivirals (DAAs) in the management of HCV infection in the CKD population.
T
he first clinical practice guideline published by Kidney Disease: Improving Global Outcomes (KDIGO) was its 2008 guideline on the prevention, diagnosis, evaluation, and treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease (CKD) (1, 2) . In the subsequent 10 years, the development of direct-acting antivirals (DAAs), which enabled a greater than 95% rate of viral eradication in CKD populations infected with HCV, prompted KDIGO to update its 2008 guideline (3, 4) . The guideline's overall objective is to inform the management of HCV infection, including the use of DAAs in adults with CKD. Its target audience includes nephrologists, transplant physicians, hepatologists, infectious disease specialists, primary care physicians, and other practitioners caring for adults with HCV infection and CKD worldwide. Like the original 2008 HCV and CKD guideline, recommendations are divided into 5 chapters addressing the detection and evaluation of HCV in CKD, treatment of HCV infection in patients with CKD, prevention of HCV transmission in hemodialysis units, management of HCV-infected patients before and after kidney transplantation, and diagnosis and management of kidney diseases associated with HCV infection.
Within the guideline, recommendations for clinical practice, implementation, and future research are highlighted. The guideline seeks to provide comprehensive guidance encompassing all aspects of managing HCV infection in CKD populations (Appendix Figure, available at Annals.org) and considers implementation across international settings where HCV and CKD are encountered. The complete version is available at www .kdigo.org and includes 66 recommendations. This synopsis focuses on 32 key recommendations relevant to clinical practice regarding HCV infection in patients with CKD. The major topics of the remaining 34 recommendations include the prevention of HCV transmission in hemodialysis units, CKD testing in HCV-infected patients, performance characteristics of noninvasive tests of hepatic fibrosis, and decisions regarding liverkidney versus kidney-only transplantation.
GUIDELINE DEVELOPMENT PROCESS, EVIDENCE GRADING, AND STAKEHOLDER CONSULTATION
The work group consisted of an international body of clinicians and researchers, including nephrologists, hepatologists, virologists, a representative from the Centers for Disease Control and Prevention (CDC), and a professional evidence review team. The work group formulated the scope of the guideline and graded evidence on the basis of the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system (5) in accordance with KDIGO's usual practice (Appendix Tables 1 and 2 , available at Annals.org).
In brief, the process involved reviewing the 2008 KDIGO guideline on HCV and CKD, as well as other HCV guidelines (American Association for the Study of Liver Diseases and Infectious Diseases Society of America [AASLD/ IDSA], European Association for the Study of the Liver, and Japanese Society for Dialysis Therapy) that had
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sections related to CKD (6 -8) , and then developing research questions for each of the chapters. On the basis of specific research questions identified by the work group, the evidence review team conducted systematic reviews on 7 topics: HCV treatment in CKD populations (chapters 2, 4, and 5), pretransplant noninvasive testing for hepatic fibrosis (chapter 1), outcome of isolation of HCV-infected patients in hemodialysis units (chapter 3), outcomes with early versus late kidney transplantation for HCV-infected patients on the waitlist (chapter 4), transplantation of kidneys from HCV-infected donors to HCV-infected recipients (chapter 4), predictors of CKD progression associated with HCV (chapter 1), and relationships between HCV and graft loss and mortality in kidney transplant recipients (chapter 4). The search parameters are presented in Appendix Table 3 (available at Annals.org). The formal literature search identified 125 eligible studies, which were summarized and assessed for quality by using the GRADE methodology (5). The work group then developed guideline statements rated as strong (level 1) or weak (level 2) on the basis of the strength of evidence from the systematic review as well as other evidence from non-CKD populations. In accordance with GRADE, the strength of the evidence supporting each guideline statement was rated from high (A) to very low (D). Guideline statements providing general guidance, and therefore not based on systematic evidence review, were labeled "nongraded."
The guideline statements and supporting text subsequently underwent external stakeholder review by individuals and organizations worldwide with expertise in the field. The final document incorporated comments and suggestions from the external review where appropriate. 
CHAPTER 1: RECOMMENDATIONS RELATED TO
. We recommend using an immunoassay followed by nucleic acid testing (NAT) if immunoassay is positive (1A).
Hepatitis C virus infection is more prevalent among persons with CKD than it is in the general population. Approximately 5% of patients receiving incident dialysis have HCV-positive results on enzyme-linked immunosorbent assay (EIA) (9), compared with an estimated 1% of the general U.S. population (10) . Recent studies implicated HCV infection as an independent risk factor for faster rates of CKD progression (11) , related in part to the association of HCV with several glomerulonephritides but probably also independent of this connection. The AASLD/IDSA and CDC recommend 1-time HCV testing for the 1945 to 1965 birth cohort because of a higher prevalence of the virus in this group (6, 12) . In addition, the AASLD/IDSA and CDC recommend HCV testing for high-risk patients, including those who have ever required long-term hemodialysis, have used injection or intranasal drugs, received a solid organ transplant before July 1992, have HIV infection, or were ever incarcerated (6) ( Table 1) . The recommendation to screen all patients for HCV at the time of initial CKD evaluation is based on these guideline recommendations, the higher prevalence of HCV infection among patients with CKD, and the more rapid CKD progression seen in patients with CKD and HCV infection compared with uninfected patients (13) . Future studies should determine the degree of clinical benefit of this strategy of HCV testing in patients with CKD. Repeated HCV testing is prudent for patients who may be continuously exposed to HCV, such as through ongoing drug use or long-term hemodialysis. Decisions regarding the benefit of HCV screening in patients with CKD may be informed by a recent report describing a slower decrease in glomerular filtration rate (GFR) after versus before successful HCV treatment in patients with an estimated GFR less than 60 mL/min/1.73 m 2 (14) . The prevalence of HCV in the hemodialysis population exceeds that of the general population, with approximately 10% of patients in the recent DOPPS (Dialysis Outcomes and Practice Patterns Study) analyses having positive results on EIA, also known as anti-HCV or HCV antibody testing (9, 15) . The high HCV prevalence occurs as a result of the high prevalence of HCV (9) as well as nosocomial transmission within hemodialysis units. Testing for HCV before the start of in-center hemodialysis (including a transition from another dialysis method) and upon transfer between hemodialysis facilities provides the opportunity to identify patients potentially exposed to HCV at the previous facility. Acute HCV infection in hemodialysis units is identified by monitoring liver biochemical test results for increases above baseline, which may suggest acute HCV infection and prompt testing for HCV viremia several months before EIA testing shows positive results. The recommendation for HCV testing in patients receiving peritoneal dialysis or home hemodialysis is based on limited evidence; nevertheless, it is a prudent approach. Testing for HCV is recommended for kidney transplant candidates to determine who is at risk for progressive hepatic disease and might benefit from an HCV-infected donor kidney and to select the optimal HCV treatment strategies for transplant candidates.
Recommendations Related to HCV Testing in
Nucleic acid testing confirms active HCV infection (HCV RNA positivity or viremia); however, EIA followed by NAT for patients with positive EIA results, ideally via reflex testing, is a reasonable approach with adequate sensitivity and specificity in immunocompetent patients. Nonetheless, NAT is the most appropriate firstline test for immunocompromised kidney transplant recipients, and possibly for patients receiving hemodialysis, because of concerns regarding delayed seroconversion in acute HCV infection (the window period). The choice between EIA and NAT is informed by the prevalence and incidence of HCV in individual hemodialysis units, because the risk for false-negative EIA results rises with increasing HCV prevalence (closely associated with incidence) in the dialysis population (1). The development of DAAs has changed the approach to HCV treatment in patients with CKD since the 2008 guideline. Interferon treatment no longer is recommended because of high adverse event rates and modest sustained virologic response (SVR) rates of 37% to 41% (16, 17) . Moreover, interferon is contraindicated in kidney transplant recipients because of a high risk for acute rejection and allograft loss (18) . Treatment with DAAs achieves SVR rates of 90% to 100%, with few adverse events, even in patients with CKD G4 to G5, patients with end-stage kidney disease (ESKD), and kidney transplant recipients (19 -22) . All patients with CKD should be evaluated for DAA treatment, with the specific regimen determined by HCV genotype, viral load, treatment history, GFR, hepatic fibrosis stage, and kidney and liver transplant candidacy and after consideration of drug-drug interactions. Figure 1 presents a treatment algorithm based on CKD stage and HCV genotype.
CHAPTER 2: RECOMMENDATIONS RELATED
The evidence base regarding DAA treatment in CKD populations is evolving rapidly, requiring professional organizations to frequently update recommendations regarding choice of antiviral regimens. Clinicians should refer to www.HCVguidelines.org, a useful resource that is updated frequently to reflect new evidence (6) . Key studies in CKD populations include C-SURFER, a randomized controlled trial of immediate versus delayed treatment with a 12-week course of elbasvir and grazoprevir in 224 patients with HCV genotype 1 and CKD G4 to G5 (76% with ESKD) (22) . The SVR rate was 94% in patients who received immediate treatment and 98% in those whose therapy was deferred (19) . No patients discontinued treatment because of adverse events. Likewise, the pangenotypic regimen of glecaprevir and pibrentasvir for 12 weeks resulted in a 98% SVR rate in 104 patients with CKD G4 to G5 (82% with ESKD) (21) . Four patients discontinued treatment, but 3 of them achieved an SVR. Although studies have reported the use of sofosbuvir-based regimens in CKD G4 to G5 and ESKD, sofosbuvir is excreted renally and is not approved by the U.S. Food and Drug Administration (FDA) for use in patients with a GFR below 30 mL/min/1.73 m 2 . Extrapolation of data from several studies in non-CKD populations (which probably included some patients with CKD G1 to G3b) (23, 24) has shown that patients with CKD who have a GFR of at least 30 mL/ min/1.73 m 2 may receive treatment with any licensed DAA regimen. Patients with a GFR below 30 mL/min/ 1.73 m 2 should receive therapy with the specific regimens outlined earlier ( 
We recommend that calcineurin inhibitor levels be monitored during and after DAA treatment (1B).
Studies of DAA treatment in kidney transplant recipients generally have enrolled patients with a GFR of 30 mL/min/1.73 m 2 or higher and therefore have included sofosbuvir-based regimens. Treatment with DAAs in kidney transplant recipients has resulted in SVR rates exceeding 95%. Colombo and colleagues (20) reported an SVR of 100% after 114 kidney transplant recipients received treatment with sofosbuvir and ledipasvir, with only 1% discontinuing treatment because of adverse events. A study combining kidney and liver transplant recipients demonstrated an overall SVR of 98% after treatment with glecaprevir and pibrentasvir, with all 20 kidney transplant recipients achieving an SVR (25) .
For kidney transplant recipients, the selection of DAA regimen should reflect HCV genotype, viral load, treatment history, GFR, and hepatic fibrosis stage, and particularly should consider drug-drug interactions between the DAA and other medications, notably calcineurin inhibitors. Information on drug-drug interactions is available at www.hep-druginteractions.org, which is updated frequently on the basis of new data. Clinicians providing care for HCV-infected kidney transplant recipients should have a heightened awareness of changes in allograft function, particularly in those receiving calcineurin inhibitors, because increased or decreased plasma levels have been described as a result of drug-drug interactions with DAAs. Treatment of HCV infection in kidney transplant recipients should follow the algorithm in Figure 2 and the specific regimens outlined in Table 2 . Although early evidence suggests that most DAAs may be used safely in patients receiving transplant immunosuppressive agents, and most DAAs are FDA-approved for patients with a GFR above 30 mL/min/1.73 m 2 , the clinical experience with DAAs in organ transplant recipients remains relatively sparse; therefore, careful attention to treatment in this population is prudent.
Timing of Treatment in Kidney Transplant Candidates
Treat kidney transplant candidates in collaboration with the transplant center to optimize timing of therapy (not graded).
As a result of the universally high SVR rates in all CKD populations, decisions regarding optimal timing of treatment for transplant candidates should include the transplant center (26) . Kidney transplant candidates with HCV who are willing to accept a kidney from an HCV-infected donor may benefit from a shorter waitlist time if they forgo treatment until after receiving the HCV-positive donor organ, a graft that might otherwise be discarded (27) . However, kidney transplant candi- Synopsis of KDIGO 2018 Guideline on HCV in CKD CLINICAL GUIDELINE dates with compensated cirrhosis from HCV should be considered for pretransplant treatment to induce fibrosis regression after achieving SVR to allow kidney-only transplantation.
All treatment candidates should undergo testing for HBV infection prior to therapy (not graded).
Assessment for unrecognized hepatitis B virus (HBV) infection before DAA treatment is recommended because of recent reports of fulminant HBV reactivation during DAA therapy (28) . The prevalence of HBV in the hemodialysis facilities sampled in DOPPS was 3.0% (29) , suggesting that the prevalence in patients with CKD probably exceeds that of the general population. Testing should include hepatitis B surface antigen, surface antibody, and core antibody and, if required by test results, HBV DNA. * Therapy duration for all regimens is usually 12 wk, but readers should consult guidelines from the AASLD/IDSA or European Association for the Study of the Liver for latest guidance. We recommend that patients with CKD and a GFR ≥30 mL/min/1.73 m 2 (CKD G1-G3b) receive treatment with any licensed direct-acting antiviral regimen. Sofosbuvir/velpatasvir-based regimens are not listed here because they were not formally reviewed by the evidence review team at the time of guideline publication. However, these regimens may be considered in patients with a GFR ≥30 mL/min/1.73 m 2 given their availability in certain jurisdictions. † For patients with CKD G5 who are receiving peritoneal dialysis, no evidence or data are available; therefore, following the proposed regimens for patients receiving hemodialysis is reasonable.
CHAPTER 4: RECOMMENDATIONS RELATED TO THE MANAGEMENT OF HCV-INFECTED PATIENTS BEFORE AND AFTER KIDNEY TRANSPLANTATION
We recommend kidney transplantation as the best therapeutic option for patients with CKD G5, irrespective of presence of HCV infection (1A).
Timing of HCV treatment in relation to kidney transplantation (before vs. after) should be based on donor type (living vs. deceased donor), wait-list times by donor type, center-specific policies governing the use of kidneys from HCV-infected deceased donors, HCV genotype, and severity of liver fibrosis (not graded).
We recommend that all HCV-infected patients who are candidates for kidney transplantation be considered for DAA therapy, either before or after transplantation (1A).
We suggest that HCV-infected kidney transplant candidates with a living kidney donor can be considered for treatment before or after transplantation according to HCV genotype and anticipated timing of transplantation (2B).
We suggest that if receiving a kidney from an HCV-positive donor improves the chances for transplantation, the HCV NAT-positive patient can undergo transplantation with an HCV-positive kidney and be treated for HCV infection after transplantation (2B).
Use of Kidneys From HCV-Infected Donors
We recommend that all kidney donors be screened for HCV infection with both immunoassay and NAT (if NAT is available) (1A).
‡ Little published evidence exists to guide treatment regimens in kidney transplant recipients with a GFR <30 mL/min/1.73 m 2 (CKD G4T-G5T). For these patients, regimens should be selected to avoid drug-drug interactions, particularly with calcineurin inhibitors. § Also known as the PrOD or 3D regimen. ͉͉ Based on reference 25. ¶ As suggested by AASLD/IDSA guidelines (www.HCVguidelines.org).
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We recommend that transplantation of kidneys from HCV NAT-positive donors be directed to recipients with positive NAT (1A). 4.2.3. After the assessment of liver fibrosis, HCVpositive potential living kidney donors who do not have cirrhosis should undergo HCV treatment before donation; they can be accepted for donation if they achieve sustained virologic response (SVR) and remain otherwise eligible to be a donor (not graded).
Hepatitis C virus infection is not a contraindication to kidney transplantation. The mortality rates are much lower in HCV-infected kidney transplant recipients than in HCV-infected patients on the transplant waitlist (30 -32) . Nevertheless, HCV-infected kidney transplant recipients have had increased mortality (33, 34) , allograft loss (35, 36) , posttransplant diabetes (37) (38) (39) , and glomerulonephritis (40, 41) compared with noninfected patients; therefore, DAA treatment is critical, and the decision regarding pre-versus posttransplant treatment must be individualized to maximize the benefit for each patient (26) . Incorporating the judgment of the transplant center and other specialists in these complex decisions is critical. Specific details regarding evidencebased DAA treatment regimens, timing of treatment, and the importance of monitoring GFR and calcineurin inhibitor levels during and after treatment are discussed elsewhere (chapter 2, section 2.4).
HCV-Infected Kidney Donors
Potential deceased donors require HCV testing with both EIA and NAT to determine whether viremia is present. Kidneys from HCV-infected deceased donors should be directed to recipients with positive NAT results. This practice has been modified by the development of research protocols describing transplantation of kidneys from NAT-positive donors to non-HCVinfected recipients who received immediate DAA treatment; these studies have reported a 100% SVR rate with good short-term allograft outcomes (42, 43) . This practice may become more widespread in the future but for now should be restricted to investigational settings, although this statement may require revision as new evidence accrues. Potential living kidney donors with HCV infection should receive DAA treatment and, upon achieving an SVR, be re-evaluated to ensure that they are still appropriate kidney donors. 
CHAPTER 5: RECOMMENDATIONS RELATED TO THE DIAGNOSIS AND MANAGEMENT OF KIDNEY DISEASES ASSOCIATED WITH HCV INFECTION
We recommend that patients with HCVassociated glomerular disease be treated for HCV (1A).
We recommend that patients with HCVrelated glomerular disease showing stable kidney func-
. We recommend rituximab as the first-line immunosuppressive treatment (1C).
The role of DAAs in managing HCV-associated glomerulonephritis, including HCV-associated mixed cryoglobulinemia and membranoproliferative glomerulonephritis, has become clearer in recent years. Rates of SVR have ranged from 74% to 83% in studies of DAAs for HCV-associated glomerulonephritis, with low adverse event rates (44 -46) . It is important to note that DAA treatment leads to diminished proteinuria and increased GFR and quality of life, but studies have been limited to patients with stable GFR and without rapidly progressive glomerulonephritis, cryoglobulinemic vasculitis, or nephrotic-range proteinuria. In these more urgent scenarios, immunosuppressive therapy should be administered concomitantly with DAAs, and plasma exchange should be considered. Among immunosuppressive agents, rituximab is the best-studied agent for HCVrelated glomerulonephritis (47, 48) . Before initiating rituximab therapy, patients should be assessed for HBV infection to avoid fulminant hepatitis resulting from HBV reactivation.
DISCUSSION
The 2018 KDIGO clinical practice guideline on HCV and CKD represents a major update to the original 2008 guideline. Because of the efficacy of DAAs in populations with CKD, including CKD G4, G5, and G5D, as well as in kidney transplant recipients, the approach to HCV management has evolved dramatically in the past 10 years. The ability to eradicate HCV with DAA treatment influenced all chapters of the 2018 update. Medium-sized prospective cohort studies and randomized controlled trials in CKD G4 and G5, as well as in patients receiving hemodialysis and in kidney transplant recipients, have consistently revealed SVR rates of 90% to 100%. The results add to the evidence base supporting efficacy of DAA treatment in patients without CKD and directly translate to the recommendation to evaluate treatment candidacy for all HCV-infected patients with CKD. Direct-acting antiviral-based treatment of HCV-associated glomerular disease is another area of rapid change, with a shift in focus from immunosuppression to HCV eradication as the first-line management approach for most patients.
The potential to cure HCV infection also affects the recommendations on HCV testing. The CDC and AASLD/IDSA already recommend 1-time HCV testing for the 1945 to 1965 birth cohort and for patients with a high risk for HCV infection, which includes several risk factors common to patients with CKD. Nephrologists generally recommend HCV testing for patients under evaluation for glomerular disease; in addition, the yield of HCV testing in patients with CKD is higher because of the increased prevalence of HCV in the CKD population. The growing evidence base supporting an association between HCV infection and faster progression of CKD to ESKD also supports the recommendation to test all patients at initial CKD evaluation. If future investigation replicates the early finding that DAA treatment may slow CKD progression (49), the imperative for HCV testing of all patients with CKD would gain strength because it would offer a novel avenue to slow CKD progression (50) .
Finally, the efficacy of DAA therapy in patients with advanced kidney disease, including those receiving dialysis and kidney transplant recipients, has greatly affected the approach to HCV infection in kidney transplant candidates. Careful attention to strategies for timing HCV treatment that maximize benefit to individual patients as well as those that improve the use of HCV-infected deceased donor kidneys are becoming increasingly important (27) . The new development in which HCV-infected organs are transplanted to HCVuninfected persons who receive immediate posttransplant DAA treatment may represent a major advance (42, 43, 51), but it is a new field that warrants further investigation. Clinicians treating HCV-infected kidney transplant recipients should have heightened awareness for changes in allograft function, particularly in patients receiving calcineurin inhibitors. Until more extensive experience is available to ensure the safety of DAAs, with the transplanted kidney functioning in the common GFR range of 30 to 60 mL/min/1.73 m 2 , kidney allograft function should be monitored closely while these patients are receiving DAA therapy.
Future research in HCV and CKD will probably shift to implementation science, as well as to costeffectiveness and decision analysis. What are the best approaches to identify HCV-infected patients with CKD? How do we ensure equitable access to DAA treatment? Does HCV treatment actually slow CKD progression? What is the optimal timing of HCV treatment in patients whose kidney disease may progress to ESKD? What are the cost implications of strategies designed to test all patients with CKD and to provide treatment to all HCV-infected persons? The answers to these and other questions will probably guide the future of HCV management in patients with CKD.
We are optimistic that the current KDIGO guideline will increase attention on the intersection between HCV and CKD and spur future investigation into new directions to improve the care of this patient population. Note: The development of this guideline is strictly funded by KDIGO, and neither KDIGO nor its guideline work group members sought or received monies or fees from corporate or commercial entities in connection with this work.
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